Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, targets the inflammasome pathway to address conditions such as recurrent pericarditis and myocarditis. The company operates clinical programs, including the MAVERIC and ARCHER programs, to evaluate CardiolRx™ in pivotal trials. Cardiol Therapeutics primarily serves patients suffering from inflammatory heart diseases and operates in the United States and Canada.
